NovoBiotic Pharmaceuticals is a biotechnology company focused on discovery and development of new drugs from natural sources with a particular focus on the discovery of new antibiotics targeting serious drug-resistant infections. While many marketed antibiotics are derived from microbes found in the soil, few new classes have been introduced in more that 50 years. Big pharma have exhaustively screened the readily culturable microbes, which represent <1% of microbes in the environment but the vast majority of microbes in nature have remained uncultured and inaccessible to drug discovery. NovoBiotic has discovered a unique, proprietary method to isolate and cultivate previously unculturable microorganisms in the laboratory, giving NovoBiotic sole access to a virtually unlimited and as yet unexploited source of novel natural product compound diversity. This unique access to natural product diversity represents one of the most valuable assets for modern drug discovery. With the focus on identifying new antibiotics from these novel sources, longer term the company will leverage the value of this unique, microbe-derived chemical diversity in therapeutic areas such as oncology, atherosclerosis, and inflammatory diseases.